[go: up one dir, main page]

DE60323634D1 - Nichtimmunsuppressive immunogene oder vakzinzusammensetzung enthaltend ein mutiertes e7-protein vom humanen papilloma-virus hpv-16 - Google Patents

Nichtimmunsuppressive immunogene oder vakzinzusammensetzung enthaltend ein mutiertes e7-protein vom humanen papilloma-virus hpv-16

Info

Publication number
DE60323634D1
DE60323634D1 DE60323634T DE60323634T DE60323634D1 DE 60323634 D1 DE60323634 D1 DE 60323634D1 DE 60323634 T DE60323634 T DE 60323634T DE 60323634 T DE60323634 T DE 60323634T DE 60323634 D1 DE60323634 D1 DE 60323634D1
Authority
DE
Germany
Prior art keywords
amino acid
protein
acid sequence
immunogenic
unimmunsuppressive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60323634T
Other languages
English (en)
Inventor
Daniel Zagury
Buanec Helene Le
Bernard Bizzini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neovacs SA
Original Assignee
Neovacs SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neovacs SA filed Critical Neovacs SA
Application granted granted Critical
Publication of DE60323634D1 publication Critical patent/DE60323634D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16311Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60323634T 2002-04-24 2003-04-04 Nichtimmunsuppressive immunogene oder vakzinzusammensetzung enthaltend ein mutiertes e7-protein vom humanen papilloma-virus hpv-16 Expired - Lifetime DE60323634D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0205173A FR2839072A1 (fr) 2002-04-24 2002-04-24 Produit d'expression d'un adn codant une proteine e7 mutee de hpv-16, composition immunogene contenant ledit produit d'expression et son procede de preparation
PCT/FR2003/001082 WO2003090667A2 (fr) 2002-04-24 2003-04-04 Composition immunogene ou vaccinale non immunosuppressive, comprenant une proteine e7 mutee du virus hpv-16

Publications (1)

Publication Number Publication Date
DE60323634D1 true DE60323634D1 (de) 2008-10-30

Family

ID=28799908

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60323634T Expired - Lifetime DE60323634D1 (de) 2002-04-24 2003-04-04 Nichtimmunsuppressive immunogene oder vakzinzusammensetzung enthaltend ein mutiertes e7-protein vom humanen papilloma-virus hpv-16

Country Status (13)

Country Link
US (1) US7314629B2 (de)
EP (1) EP1509543B1 (de)
JP (1) JP2005532298A (de)
CN (1) CN1656116A (de)
AT (1) ATE408620T1 (de)
AU (1) AU2003249143B2 (de)
BR (1) BR0309491A (de)
CA (1) CA2483819C (de)
DE (1) DE60323634D1 (de)
DK (1) DK1509543T3 (de)
ES (1) ES2312801T3 (de)
FR (1) FR2839072A1 (de)
WO (1) WO2003090667A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417430D0 (en) * 2004-08-05 2004-09-08 Uc3 A novel HPV vaccine comprising peptides from host cell proteins
US8399610B2 (en) * 2004-08-05 2013-03-19 University College Cardiff Consultants Limited HPV vaccine comprising peptides from host cell proteins
US8452541B2 (en) * 2007-06-18 2013-05-28 Microsoft Corporation Vaccine design methodology
US20090117140A1 (en) * 2007-09-26 2009-05-07 Mayumi Nakagawa Human papilloma virus dominant CD4 T cell epitopes and uses thereof
US8466259B2 (en) * 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
JP5146113B2 (ja) * 2008-05-30 2013-02-20 住友電装株式会社 電気接続箱
US8287880B2 (en) 2009-06-02 2012-10-16 National Health Research Institutes Lipidated vaccine against dengue virus infection
TWI409275B (zh) * 2009-06-22 2013-09-21 Nat Health Research Institutes 脂質化腫瘤相關抗原及其免疫治療的組成物及方法
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
CN105177047B (zh) * 2014-08-12 2018-02-02 广东拓谱康生物科技有限公司 携带人乳头瘤病毒16型突变型E7m94抗原基因的重组腺相关病毒载体及其构建方法与应用
CN105177048B (zh) * 2014-08-12 2018-02-02 广东拓谱康生物科技有限公司 携带人乳头瘤病毒16型多点突变型E7mm抗原基因的重组腺相关病毒载体及其构建方法与应用
CN114075293B (zh) * 2020-08-14 2022-11-15 长沙诺盟生物医药有限公司 包含突变的hpv16 e6蛋白的融合蛋白和疫苗组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2038581A1 (en) * 1990-03-20 1991-09-21 Martin Muller Seroreactive epitopes of human papillomavirus (hpv) 16 proteins
AUPN015794A0 (en) * 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
EP1108035B1 (de) * 1998-09-04 2007-08-08 Sanofi Pasteur Limited Behandlung von gebärmutterhalskrebs
ES2233437T3 (es) * 1999-08-25 2005-06-16 MERCK & CO., INC. Genes sinteticos del papilomavirus optimizados para expresion en celulas humanas.
FR2794371B1 (fr) * 1999-10-07 2004-06-18 Biovector Therapeutics Fragments proteiquespolyepitopiques, leur obtention et leurs utilisations notamment en vaccination

Also Published As

Publication number Publication date
ATE408620T1 (de) 2008-10-15
JP2005532298A (ja) 2005-10-27
CA2483819A1 (fr) 2003-11-06
CN1656116A (zh) 2005-08-17
WO2003090667A2 (fr) 2003-11-06
US7314629B2 (en) 2008-01-01
ES2312801T3 (es) 2009-03-01
CA2483819C (fr) 2013-01-22
EP1509543A2 (de) 2005-03-02
US20060233820A1 (en) 2006-10-19
EP1509543B1 (de) 2008-09-17
FR2839072A1 (fr) 2003-10-31
WO2003090667A3 (fr) 2004-04-01
DK1509543T3 (da) 2008-12-15
AU2003249143A1 (en) 2003-11-10
BR0309491A (pt) 2005-02-15
AU2003249143B2 (en) 2008-05-08

Similar Documents

Publication Publication Date Title
JP2019013251A5 (de)
JP2018510622A5 (de)
DE60323634D1 (de) Nichtimmunsuppressive immunogene oder vakzinzusammensetzung enthaltend ein mutiertes e7-protein vom humanen papilloma-virus hpv-16
BRPI0412799A (pt) imunógeno, composição, ácido nucleico, célula recombinante, métodos para preparar um polipeptìdeo, para induzir um a resposta imune protetora em um paciente e para induzir uma resposta anamnésica em um paciente, e, seqüência de ácido nucleico otimizada de levedura
CO5700784A2 (es) Polipeptidos de virus de papiloma humano y composiciones in- munogenas
ATE209216T1 (de) Cyclosporin-derivate mit anti-hiv-wirkung
PL363071A1 (pl) Sposoby i kompozycje dla zmniejszenia replikacji HIV-1
WO2004084805A3 (en) Acetylated tat polypeptides and methods of use thereof
ATA17892000A (de) Vakzin-zusammensetzung
JP2018504419A5 (de)
PE20010704A1 (es) Composicion farmaceutica que comprende un antigeno
EP2383285A3 (de) Peptidsequenzen und Zusammensetzungen
JP2015504052A5 (de)
RU2018105007A (ru) Композиции против аллергии на кошек
ATE246247T1 (de) Varianten des humanen rekombinanten interferon- gamma (rhu-ifn-gamma) mit erhöhter thermischer stabilität
ATE287957T1 (de) Peptide abgeleitet vom bindungs (g) protein des respiratorisches synzytialvirus
JP2010535504A5 (de)
AU4149699A (en) Use of inactivated immunosuppressive and/or angiogenic immunogenic proteins, preparation method and pharmaceutical or vaccine uses
ATE551353T1 (de) Protein mit fusogener wirkung, nukleinsäuresequenzen, die für dieses protein codieren und pharmazeutische zusammensetzungen, die dieses enthalten
DE69508382D1 (de) Peptomere mit erhöhter immunogenizität
RU2005126236A (ru) Фьюжн-белок для подавления цервикального рака
NZ507983A (en) A polypeptide comprising the amino acid of an n- terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
NZ570708A (en) Peptides of regulatory or accessory proteins of HIV, compositions and the utilization thereof
HRP20140819T1 (hr) MUTIRANI TAT OYI PROTEIN ZA PREVENCIJU ILI LIJEÄŚENJE AIDS-a
JP2003528614A5 (de)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition